The ability of carbon nanohorns (CNHs) to cross biological barriers makes them potential carriers for delivery purposes. In this work, we report the design of a new selective antibody–drug nanosystem based on CNHs for the treatment of prostate cancer (PCa). In particular, cisplatin in a prodrug form and the monoclonal antibody (Ab) D2B, selective for PSMA+ cancer cells, have been attached to CNHs due to the current application of this antigen in PCa therapy. The hybrids Ab–CNHs, cisplatin–CNHs and functionalised-CNHs have also been synthesized to be used as control systems. The efficacy and specificity of the D2B–cisplatin–CNH conjugate to selectively target and kill PSMA+ prostate cancer cells have been demonstrated in comparison with other derivatives. The developed strategy to functionalise CNHs is fascinating because it can allow the fine tuning of both drug and Ab molecules attached to the nanostructure in order to modulate the activity of the nanosystem. Finally, the herein described methodology can be used for the incorporation of almost any drugs or Abs in the platforms in order to create new targeted drugs for the treatment of different diseases.

Targeted killing of prostate cancer cells using antibody-drug conjugated carbon nanohorns

LUCÍO BENITO, MARIA ISABEL;Meneghetti, Moreno
;
Prato, Maurizio;Vázquez, Ester;HERRERO CHAMORRO, MARIA ANTONIA
2017

Abstract

The ability of carbon nanohorns (CNHs) to cross biological barriers makes them potential carriers for delivery purposes. In this work, we report the design of a new selective antibody–drug nanosystem based on CNHs for the treatment of prostate cancer (PCa). In particular, cisplatin in a prodrug form and the monoclonal antibody (Ab) D2B, selective for PSMA+ cancer cells, have been attached to CNHs due to the current application of this antigen in PCa therapy. The hybrids Ab–CNHs, cisplatin–CNHs and functionalised-CNHs have also been synthesized to be used as control systems. The efficacy and specificity of the D2B–cisplatin–CNH conjugate to selectively target and kill PSMA+ prostate cancer cells have been demonstrated in comparison with other derivatives. The developed strategy to functionalise CNHs is fascinating because it can allow the fine tuning of both drug and Ab molecules attached to the nanostructure in order to modulate the activity of the nanosystem. Finally, the herein described methodology can be used for the incorporation of almost any drugs or Abs in the platforms in order to create new targeted drugs for the treatment of different diseases.
Pubblicato
http://pubs.rsc.org/en/Content/ArticleLanding/2017/TB/C7TB02464A#!divAbstract
File in questo prodotto:
File Dimensione Formato  
J Mat Chem B 2017_Lucio.pdf

non disponibili

Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 2.32 MB
Formato Adobe PDF
2.32 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
c7tb02464a1.pdf

non disponibili

Descrizione: Supporting information
Tipologia: Altro materiale allegato
Licenza: Copyright Editore
Dimensione 782.53 kB
Formato Adobe PDF
782.53 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2919662
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact